Your browser doesn't support javascript.
loading
Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.
Brown, Aaron C; Quiroz, José; Parikh, Devayu A; Li, Yafeng; Ritzer, Lukas; Rosen, Richard; Deobhakta, Avnish.
Afiliación
  • Brown AC; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.
  • Quiroz J; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Parikh DA; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.
  • Li Y; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ritzer L; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th Street, New York, NY, 10003, USA.
  • Rosen R; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Deobhakta A; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
BMC Ophthalmol ; 24(1): 312, 2024 Jul 29.
Article en En | MEDLINE | ID: mdl-39075390
ABSTRACT
Immune checkpoint inhibitors (ICI) such as Programmed cell Death 1 (PD-1) inhibitors have improved cancer treatment by enhancing the immune system's ability to target malignant cells. Their use is associated with immune-related adverse events (irAEs), including uveitis. The profile of pro-inflammatory cytokines underlying Anti-PD-1-induced uveitis shares significant overlap with that of non-infectious uveitis. Current corticosteroid treatments for uveitis while effective are fraught with vision threatening side effects. The cytokine profile in ICI-related uveitis has a large overlap with that of noninfectious uveitis, this overlap strongly supports the potential for therapy that activates the PD-1 axis in the eye to treat uveitis. Indeed, ICI related uveitis often resolves with cessation of the ICI, restoring the endogenous PD-1 axis. The potential benefit of targeting many pro-inflammatory cytokines via local PD-1 axis activation is mitigating ocular inflammation while minimizing adverse effects.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Citocinas / Receptor de Muerte Celular Programada 1 / Inhibidores de Puntos de Control Inmunológico Límite: Humans Idioma: En Revista: BMC Ophthalmol Asunto de la revista: OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Citocinas / Receptor de Muerte Celular Programada 1 / Inhibidores de Puntos de Control Inmunológico Límite: Humans Idioma: En Revista: BMC Ophthalmol Asunto de la revista: OFTALMOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido